Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130986 · ClinicalTrials.gov registry record · NA
Procalcitonin Antibiotic Consensus Trial (ProACT)
A NA study of Lower Respiratory Tract Infection (LRTI), sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 1,664
- Enrollment target
- 13
- Study locations
NCT02130986: Completed NA study of Lower Respiratory Tract Infection (LRTI), sponsored by University of Pittsburgh.
NCT02130986 is a NA study of Lower Respiratory Tract Infection (LRTI) that has completed, run by University of Pittsburgh. The registered enrollment target is 1,664 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (19% higher). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02130986, a NA study of Lower Respiratory Tract Infection (LRTI), has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,664 participants
- Enrollment target
- 13
- Study locations
Study Summary
The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory Tract Infection (LRTI).
Primary Outcome
Total antibiotic exposure, defined as the total number of antibiotic-days by Day 30.
Conditions Studied
Interventions
- OTHER Procalcitonin level
- OTHER Results of procalcitonin (PCT) level to treating clinician
- OTHER Provide procalcitonin guideline to treating clinician
- OTHER Telephone Visit
Study Locations (13)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Pennsylvania
- Penn State Hershey College of Medicine; Milton S. Hershey Medical Center - Hershey
- University of Pittsburgh Medical Center - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Maricopa Medical Center - Phoenix
California
- University of California at Irvine Medical Center - Orange
Connecticut
- Norwalk Hospital - Norwalk
Maryland
- University of Maryland/Baltimore - Baltimore
Michigan
- Wayne State University/Detroit Receiving Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,664 participants |
| Start Date | 2014-11-03 |
| Est. Completion | 2017-07-21 |
| Phase | NA |
What the finished NCT02130986 record still lists
NCT02130986 is an interventional study that assigns participants to a tested intervention. Its 1,664 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (19% higher).
The record links to 1 condition, with Lower Respiratory Tract Infection (LRTI) appearing as the primary indexed condition, and to 4 interventions - of which Procalcitonin level is the first listed.
NCT02130986 lists 13 locations in 10 states (Massachusetts, Pennsylvania, Alabama).
Frequently Asked Questions
What is clinical trial NCT02130986 about?
NCT02130986 is a clinical study titled "Procalcitonin Antibiotic Consensus Trial (ProACT)". The ProACT study is a 5 year, multicenter study that will test the effect of implementation of a novel procalcitonin guideline on antibiotic use and adverse outcomes in Emergency Department (ED) patients with Lower Respiratory Tract Infection (LRTI).
What is the current status of trial NCT02130986?
This trial is currently completed. It is a NA study. The enrollment target is 1,664 participants. The study started on 2014-11-03. Estimated completion is 2017-07-21.
What conditions does trial NCT02130986 study?
This clinical trial studies the following conditions: Lower Respiratory Tract Infection (LRTI).
What interventions are being tested in trial NCT02130986?
The interventions under investigation include: Procalcitonin level (OTHER), Results of procalcitonin (PCT) level to treating clinician (OTHER), Provide procalcitonin guideline to treating clinician (OTHER), Telephone Visit (OTHER).
Who is sponsoring clinical trial NCT02130986?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02130986 being conducted?
This trial has 13 study locations across Alabama, Arizona, California, Connecticut, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02130986's enrollment target sits among peer trials
1,664 62nd of 2000 higher than 1,939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI